Evidence map›Paper›PMID 39372204›Full record

ArticleFrontiers in pharmacology2024

Mitigative role of cysteamine against unilateral renal reperfusion injury in Wistar rats.

Babatunde Adebola Alabi, Okot-Asi Nku-Ekpang, Sodiq Kolawole Lawal, Ezekiel Olugbenga Iwalewa, Temidayo Omobowale, Richard Ajike, Ridwan Abiodun Lawal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Babatunde Adebola AlabiDepartment of Pharmacology and Therapeutics, Bowen University, Iwo, Nigeria.
Okot-Asi Nku-EkpangDepartment of Physiology, University of Calabar, Calabar, Cross River, Nigeria.
Sodiq Kolawole LawalDepartment of Anatomy, University of Botswana, Gaborone, Botswana.
Ezekiel Olugbenga IwalewaDepartment of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Oyo, Nigeria.
Temidayo OmobowaleDepartment of Veterinary Medicine, University of Ibadan, Ibadan, Oyo, Nigeria.
Richard AjikeDepartment of Physiology, Ladoke Akintola University of Technology, Ogbomosho, Oyo, Nigeria.
Ridwan Abiodun LawalDepartment of Biochemistry, University of Lagos, Lagos, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ischemia-reperfusion injury (IRI) is unavoidable during kidney transplant and it is responsible for delayed or non-function after kidney transplantation. Cysteamine is the standard drug in the management of nephropathic cystinosis and its extra-renal complications. Thus, we designed this study to investigate its potential against renal reperfusion injury. Results: Significant elevation of H Conclusion: Based on its activity against inflammation, apoptosis, and free radical-induced stress, cysteamine has great potential to be used as a kidney transplant pre-operative drug to prevent renal reperfusion injury.

Indexed as

caspase 3inflammatory mediatorskidney transplantrenal injurytranscription factor

Identifiers

PMID39372204
PMCPMC11450295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.